The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.


Psoriasis is a systemic inflammatory disease

Gain insight into the prevalence of psoriasis, how it affects patients at a cellular level, and what phosphodiesterase 4 (PDE4) inhibition may mean for treatment

About Psoriasis

Inflammation is a tightly regulated, naturally occurring part of the body’s protective response to injury or infection, intended to prevent damage to surrounding tissue. In response to inflammation, several mechanisms work to regulate this immune response. Thus, these regulatory mechanisms help to establish immune homeostasis.1

The most common form of psoriasis, plaque psoriasis, manifests as well-demarcated, raised, scaly, erythematous skin lesions. These lesions can appear anywhere on the body but are most commonly found on the scalp, elbows, nails, lower back, and knees.2,3

Psoriasis plaque formation is thought to be caused by dysregulated immune activity within the skin. This dysregulation can lead to an imbalance and overproduction of pro-inflammatory cytokines such as TNF-α, IL-23, IL-17, and IFN-γ in immune cells.2,4,5

These cytokines promote chronic inflammation of the epidermis and induce keratinocyte hyperproliferation. These changes result in redness, itching, epidermal thickening, and scaly plaques.3-10

Where can I find more information and support?


  1. Van Parijs L, et al. Science. 1998;280:243-248.
  2. Mason AR, et al. Cochrane Database Syst Rev. 2013;3:CD005028.
  3. National Psoriasis Foundation. An Overview of Psoriasis and Psoriatic Arthritis. Portland, OR: National Psoriasis Foundation; 2009.
  4. Lowes MA, et al. Nature. 2007;445(7130):866-873
  5. Nestle FO, et al. N Engl J Med. 2009;361:496-509.
  6. Schön MP, et al. N Engl J Med. 2005;352(18):1899-1912.
  7. Perera GK, et al. Annu Rev Pathol. 2012;7:385-422.
  8. Balato A, et al. Psoriasis. Rijeka, Croatia: InTech Europe; 2012.
  9. Dogan S, et al. Psoriasis—Types, Causes and Medication. Rijeka, Croatia: InTech Europe; 2013.
  10. Menter A, et al. J Am Acad Dermatol. 2011;65(1):137-174.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.